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AbstrACt
Introduction Anticipated or actual pain in neonates 
results in use of paracetamol for prolonged pain relief 
in many neonatal intensive care units. Clinical trials 
examining safety of paracetamol exposure in neonates 
have been of short duration (1–3 days) and hepatic 
biomarkers and paracetamol metabolism are rarely 
reported in the same studies. We aim to investigate the 
safety (hepatic tolerance) and effectiveness of prolonged 
paracetamol exposure in neonates by measuring hepatic 
biomarkers, plasma concentrations of paracetamol and 
its metabolites and pain scores. In addition, we study a 
possible interaction between ethanol and paracetamol.
Methods and analysis A multicentre interventional 
cohort study. Neonates of any gestational age and 
up to 44 weeks postmenstrual age, treated with oral 
or intravenous paracetamol can be included. Alanine 
aminotransferase (ALT) and bilirubin are measured at 
baseline or within 24 hours after treatment initiation. 
P-paracetamol and metabolites are measured at steady 
state and every 2 days (opportunistically) together with ALT 
and bilirubin and lastly after discontinuation of treatment. 
COMFORT neo pain scores are collected longitudinally. 
COMFORT neo pain scores and population pharmacokinetic 
analysis of paracetamol samples will be analysed 
simultaneously using non-linear mixed effects models. One 
and two compartment models with first-order elimination 
will be tested for disposition. In addition, plasma ethanol 
is measured if the patient receives concomitant treatment 
with intravenous or oral phenobarbital containing ethanol 
as an excipient.
Ethics and dissemination Inclusion of patients can be 
postponed 24 hours after the first paracetamol dose. This 
is intended to make the inclusion process less stressful 
for parents. This study uses standard dosing strategies. 
The potential risks are additional blood samples, which are 
collected opportunistically to reduce additional heel pricks.
trial registrationnumber Ethics Comittee: 
H-17027244, EudraCT no: 2017-002724-25, BFH-2017–
106, 05952.
IntroduCtIon
Adequate pain management in neonates is a 
major issue in neonatal care. Anticipated or 
actual pain in neonates results in extended 
use of pain medications, and paracetamol is 
used for pain relief in almost every neonatal 
intensive care unit (NICU).1 Clinical trials 
examining safety of paracetamol exposure 
in neonates are primarily of short dura-
tion (1–3 days) and hepatic biomarkers and 
paracetamol metabolism are seldom reported 
in the same studies.2–4 Since paracetamol 
is widely used as prolonged treatment in 
neonates and has a clinical significant opioid-
sparing effect,5 it is highly relevant to investi-
gate safety of prolonged intravenous or oral 
paracetamol. With emphasis on increased 
risk of hepatic toxicity, for example, by 
What is already known on this topic?
 ► In neonatal pain paracetamol is increasingly pre-
scribed to reduce opioid use, and it has been shown 
to have opioid-sparing effect.
 ► Prospective data suggest a good tolerability and 
no major adverse events including the absence of 
drug-induced hepatic toxicity when administered for 
3 days or less.
 ► A few cases have described paracetamol overdos-
ing in neonates showing variable increase in hepatic 
biomarkers. All were treated with N-acetylcysteine 
and recovered without sequelae.
What this study hopes to add?
 ► Safety and pharmacokinetic information on pro-
longed use (>72 hours) of paracetamol in term and 
preterm neonates.
 ► Potential changes in hepatic biomarkers (bilirubin, 
alanine aminotransferase and coagulation factors II, 
VII and X) after prolonged (>72 hours) paracetamol 
administration in neonates.
 ► Data regarding plasma paracetamol concentrations 
and analgesic effect.
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induction of the CYP450 oxidative system due to long-
term exposure of paracetamol. This mechanism may be 
superimposed by combination with ethanol-containing 
drugs, which are metabolised by the same pathways. The 
PARASHUTE study: intravenous and oral paracetamol 
in neonates: safety and ethanol-drug interaction aims to 
improve the knowledge on safe and effective paracetamol 
treatment strategies in neonates.
Paracetamol metabolism
Paracetamol (N-acetyl-p-aminophenol or acetami-
nophen) is used for its antipyretic and weak analgesic 
effect. In children, paracetamol is metabolised mainly in 
the liver through three metabolic pathways: glucuroni-
dation, sulfation and oxidation (figure 1). The contribu-
tion of each metabolic pathway differs by age. Sulfation 
is considered the major pathway in young children6–8 
and shows no sign of saturation after up to 20 mg/kg 
intravenous paracetamol neonates<32 weeks gestational 
age.9 The glucuronidation pathway reaches adult levels 
around 12 years of age.7 One trial found no evidence of 
glucuronidation upregulation after up to 12 repeated 
paracetamol doses in neonates and infants,8 which previ-
ously was the understanding in both adults and children.8 
The oxidation pathway accounts for <10% in adults10 11 
and occurs primarily via cytochrome P450 2E1 enzyme 
(CYP2E1). The product of oxidation is N-acetyl-p-ben-
zoquinone imine (NAPQI), which is excreted in urine 
as conjugates with mercapturic acid and cysteine. These 
metabolites may provide an indirect estimate of NAPQI 
formation.12 CYP2E1 activity is lower in neonates and 
increases gradually during the first 90 days of life.13 
Hepatic micro samples have shown less CYP2E1 protein 
in samples from neonates compared with infants, chil-
dren and young adults.14 All metabolites are excreted 
in urine and have no analgesic effect.12 Less than 4% is 
excreted unchanged in the urine in all ages.7 10 15 Overall 
clearance is reduced in neonates, that is, very preterm: 
0.090 L/hour/kg, preterm 0.116 L/hour/kg and term 
infants 0.170 L/hour/kg4 and reaches 90% of adult 
values at 1 year of age.
safety and repeated dosages
Repeated doses of paracetamol administered to neonates 
could shift the metabolism towards oxidation via CYP2E1 
and formation of NAPQI. In adults the sulfation pathway 
is saturable and eventually the glucuronidation pathway 
at supratherapeutic doses.16 17 The risk of hepatotox-
icity associated with paracetamol is caused by NAPQI 
(figure 1). Conjugation with glutathione renders NAPQI 
non-toxic. If glutathione becomes depleted by 70% or 
more, NAPQI formation rises, leading to mitochondrial 
dysfunction, cell death and necrosis.18 As suggested from 
case reports of paracetamol overdosing,19 neonates are 
capable of forming NAPQI but appear to have a lower 
incidence of hepatic failure than adults.20 This may be 
explained by relative immaturity of the CYP450 oxidation 
system and a larger sulfation capacity.14 In addition, a 
relatively larger liver volume per kilogram found in chil-
dren may contribute to the low incidence.21
Three studies examined repeated intravenous parac-
etamol administration in neonates for: 31 hours, 48 hours 
and 4 days (range 1–9 days).2–4 Two of the studies 
measured paracetamol, paracetamol metabolites and 
hepatic biomarkers (bilirubin, alanine aminotransferase 
[ALT], aspartate aminotransferase [AST])2 4 and one 
trial measured paracetamol concentration and hepatic 
biomarkers (bilirubin, ALT, gamma-glutamyl transferase 
(GGT), alkaline phosphatase and albumin).3 Notably, 
paracetamol was administered repeatedly for several days 
despite a threefold increase in ALT in one patient and 
moderate increase in three patients.3 For all patients the 
authors proposed that other causes could explain the 
elevated enzymes, for example, total parental nutrition.3 
Few studies examined multiple oral doses of paracetamol 
in neonates.1 Anderson et al randomised 30 neonates 
(gestational age at birth 31–40  weeks) and infants to 
receive either paracetamol suppositories or oral solution 
administered over 2 days and measured only pharmaco-
kinetic parameters.22
A review from 2018 found 19 ongoing studies exam-
ining paracetamol for persistent ductus arteriosus, with a 
variable focus on safety with few studies reporting hepatic 
biomarkers as secondary outcome and none measures 
paracetamol metabolites.23
In one trial, a NICU database and pharmacy register 
were used to examine hepatic biomarkers in 189 neonates 
who had received repeated doses of paracetamol for a 
median of 60 hours (range 6–480 hours); no significant 
increase in ALT, AST or GGT was found.24
At least five cases of paracetamol overdoses in preterm 
neonates have been published. Doses ranged from 136 
to 446 mg/kg/dose. N-acetylcysteine was administered 
for up to 7 days. Increased international normalised ratio 
and bilirubin were seen in some cases but no other signs 
of hepatotoxicity were identified and no long-term conse-
quences were detected.19
Figure 1 Paracetamol and ethanol metabolism. The figure 
illustrates the hepatic metabolism of paracetamol through 
three different pathways: sulfation, glucuronidation and 
oxidation (cytochrome P450 2E1 [CYP2E1]). In addition, the 
metabolism of ethanol through CYP2E1 is shown.
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Analgesic effect of paracetamol and pain scores
According to a number of studies and systematic reviews, 
the way of administration, as well as, loading and mainte-
nance dose influence the target blood concentration and 
hence the analgesic effect of paracetamol.1 2 25 Existing 
evidence from one clinical trial and one newer dosing 
guideline supports a mean steady state target paracetamol 
concentration of 9–11 mg/L to achieve analgesic effect in 
neonates born between 26 and 41 gestational weeks.25–27 
This is based on pain scores (Leuven Neonatal Pain 
Score) correlated with plasma paracetamol in 19 neonates 
receiving intravenous paracetamol as single analgesic. 
However, only few data exist and treatment recommen-
dations varies between countries.26 Furthermore, two 
studies have shown significant morphine-sparing effect 
of paracetamol.5 28
Numerous pain scores are used throughout NICUs 
internationally. All Danish NICUs use the COMFORT 
neo pain score for evaluation of pain in neonates. The 
COMFORT neo pain score has been used for preterm 
and term neonates for prolonged and acute pain.29–31
Ethanol-paracetamol interaction
A number of excipients can interact with drug metabo-
lism and neonates might be more susceptible to this type 
of interaction.32 Ethanol (alcohol) is an excipient used 
in many intravenous and oral formulations, for example, 
phenobarbital, to increase solubility or act as a preserv-
ative. The pharmacokinetics and safety of ethanol in 
neonates are poorly described.32 In one trial, ethanol 
and the metabolite acetaldehyde were measured in 49 
preterm infants receiving iron and furosemide compared 
with a control group. They found that blood ethanol in 
the exposed group was low, but the acetaldehyde level 
was consistent with moderate alcohol exposure.33 Both 
paracetamol and ethanol is metabolised by CYP2E1 and 
the two substrates may compete for the limited capacity 
of the enzyme.17 Alcohol may modify CYP2E1 activity 
and deplete glutathione stores in adults.34 Addition-
ally, phenobarbital inhibit glucuronidation and poten-
tiate oxidation in vitro while human studies suggest a 
protective role in paracetamol-induced hepatotoxicity 
with no clear mechanism described.17
objectives
We aim to explore if prolonged (>72 hours) treatment 
with intravenous or oral paracetamol administered to 
neonates is associated with hepatotoxicity assessed by 
hepatic biomarkers (ALT, bilirubin and coagulation 
factor II, VII and X), paracetamol metabolites and 
paracetamol concentration (table 1).
Secondary aims are: first, to collect COMFORT neo 
pain scores and associate these with paracetamol concen-
trations. Second, to examine if ethanol-containing drugs 
(intravenous/oral phenobarbital) are associated with 
higher plasma ethanol and if the presence of ethanol 
may interact with paracetamol (table 1).
MEthods And AnAlysIs
design and population
The study is a multicentre interventional cohort study.
Neonates with any gestational age at birth and up to 
44 weeks postmenstrual age admitted to the two largest 
NICUs in Denmark, Rigshospitalet, Copenhagen Univer-
sity Hospital and Aarhus University Hospital, are eligible 
for enrolment. The neonatal patients can be included 
when they are expected to receive paracetamol (oral or 
intravenous) for >72 hours.
A recent audit of medical records from the NICU at 
Rigshospitalet revealed that approximately 10% of the 
patients received intravenous paracetamol and 5% oral 
paracetamol for >3 days (unpublished data, see online 
supplementary table S1). Hence, the patient is treated 
at the clinician’s discretion and the therapeutic strategy 
is not decided by a protocol. The duration of treatment 
and dose and administration (intravenous or oral) of 
paracetamol will follow the prescription by the attending 
physicians in the NICU (oral paracetamol was included 
in Amendment A approved March 2018). Only standard 
medicines are used. Eligible patients can be enrolled 
before or after administration of paracetamol according 
Table 1 Objectives and outcomes measures in the PARASHUTE study
Primary objective Primary outcome
To explore if long-term (>72 hours) treatment with intravenous 
or oral paracetamol administered to neonates leads to risk 
of hepatotoxicity assessed by ALT, bilirubin, paracetamol 
metabolites and paracetamol concentration.
Concentration-time data on plasma paracetamol, 
paracetamol-sulfate, paracetamol-glucuronide, oxidative 
metabolites and hepatic biomarkers (ALT, bilirubin) in 
neonates before, during and after multiple administrations 
of intravenous or oral paracetamol with focus on long-term 
(>72 hours) treatment.
Secondary objective Secondary outcome
COMFORT neo pain scores
To examine if ethanol-containing drugs (phenobarbital) causes 
a measurable rise in p-ethanol and if the presence of ethanol 
interact with paracetamol in neonates.
COMFORT neo pain scores
Levels of paracetamol metabolites and levels of p-ethanol in 
patients receiving an ethanol-containing drug compared with 
the patients not receiving an ethanol-containing drug.
ALT, alanine aminotransferase.
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to eligibility criteria (tables 2 and 3). Inclusion and 
measurement of ALT and bilirubin may be postponed 
for 24 hours (figure 2 and table 3). The subsequent 
blood sample for measuring paracetamol or its metab-
olites is drawn 18–36 hours or in close proximity after 
consecutive administrations of paracetamol. This time 
interval is chosen as steady state is expected to occur 
approximately 18–36 hours after administration of the 
drug with or without loading dose, shown by Allegaert 
et al.35 The blood sample will be repeated 0–24 hours 
after treatment discontinuation. After the first sample, 
plasma paracetamol, metabolites, ALT and bilirubin 
will be measured opportunistically36 every second day. 
After 6 days of consecutive paracetamol treatment 
samples are taken every third day to reduce the number 
of samples and to ensure feasibility of blood sampling 
during long treatment periods. Coagulation factors will 
be measured in addition if ALT increases to more than 
three times the upper normal value, this is standard 
in the NICUs involved. ALT, bilirubin and coagulation 
factors measured after treatment discontinuation will be 
collected until normalisation. Discontinuation of treat-
ment and potential follow-up are done at the discretions 
Table 2 Inclusion and exclusion criteria for the 
PARASHUTE study
Inclusion criteria Exclusion criteria
 ► Neonates any gestational age 
and weight of both sexes.
 ► Postmenstrual age up to 44 full 
weeks at inclusion.
 ► Intended treatment with 
intravenous paracetamol for any 
indication or intended treatment 
with oral paracetamol for one 
of the following indications: 
fractures, intracranial or 
extracranial haemorrhages, 
chest tubes, postoperative pain 
or painful skin lesions.
 ► Informed written consent from 
both parents or legal guardian.
 ► Inclusion can be postponed 
24 hours after treatment start.
 ► The responsible 
clinician finds the 
patient unsuitable 
for the study.
 ► Hypersensitivity 
towards 
paracetamol.
Withdrawal criteria.
The responsible clinician finds that it is no longer appropriate for a 
patient to continue in the study.
Table 3 Time schedule for participants in the PARASHUTE study 
Visit Screening
Baseline
(first liver 
biomarkers) Steady state
Opportunistic 
sampling
Measurements 
after treatment 
stop
If the patient 
receives 
intravenous or oral 
phenobarbital
Timeframe Before 
treatment 
start or within 
24 hours
18–36 hours 
after treatment 
start or as 
close to as 
possible
24 hours Maximum 24 hours 
after phenobarbital 
is administered
Eligibility Informed consent x
Inclusion and 
exclusion criteria
x x
Information to 
parents
x x
Other 
measurements
Other medicine x* x* x x
Assessment of 
serious adverse 
events
x x x
Weight and length x* x* x x
Effect parameters Hepatic 
biomarkers (ALT, 
coagulation 
factors†, bilirubin)
x‡ x x
P-paracetamol 
and metabolites
x x x
Secondary 
parameters
P-ethanol x
COMFORT neo 
scores
x§ x§ x§ x§
*Joint values.
†In case of ALT increase ≥three times UNL according to age, coagulation factors are measured.
‡Not necessary if liver biomarkers have been measured within 24 hours before inclusion. The biomarkers should preferably be taken before 
treatment start, if this is not possible a 24 hours delay is accepted, and they are then classified as ‘first liver biomarkers’.
§Measured at normal routines timepoints at the two sites.
ALT, alanine aminotransferase.
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of the responsible clinician. All paracetamol doses are 
collected, other medicines are permitted and registered 
together with diagnosis, weight, length, head circumfer-
ence, Apgar score and birth method. This study does not 
include data on perinatal exposure of paracetamol since 
paracetamol is an over-the-counter drug in Denmark and 
is used frequently. The nature of the study will therefore 
not reliably be able to backtrack during which part of the 
perinatal period the neonate has been exposed and to 
which extend. All COMFORT neo scores are collected 
during paracetamol treatment and all nurses are certified 
with a kappa value >0.65.
Patient involvement
Patients were not directly involved in the design of this 
study.
Analysis
Samples will be analysed by high-performance liquid chro-
matography-electrospray ionisation-tandem mass spec-
trometry (HPLC-ESI-MS/MS) for simultaneous quantifi-
cation of acetaminophen, acetaminophen-glucuronide, 
acetaminophen-sulfate, acetaminophen-glutathione, 
acetaminophen-cysteine and acetaminophen-N-ace-
tylcysteine in small volumes of human plasma and 
urine.37 Acetaminophen-d4 and acetaminophen-d3-sul-
fate are used as internal standards (IS). Analytes and 
IS are recovered from human plasma or serum (10 μL) 
by protein precipitation with acetonitrile. Calibration 
concentration ranges are tailored to literature values 
for each analyte for the biological matrix. Prepared 
plasma samples are analysed on an Agilent 1260 Inﬁnity 
HPLC system (inline solvent micro-degasser, binary LC 
pump, high-performance thermostatted autosampler 
and 1290 Inﬁnity thermostatted column compartment) 
interfaced with an Agilent 6460 triple-quadrupole mass 
spectrometer (Agilent Technologies, Santa Clara, Cali-
fornia, USA). MassHunter Workstation software (Agilent 
Technologies) is used for instrument control, data acqui-
sition and ESI-MS/MS parameter optimisation and 
data analysis. Chromatographic separation is achieved 
through use of an Agilent Poroshell 120 EC-C18 column 
with a 20 min run time per injected sample. The analytes 
can be accurately and precisely quantiﬁed with multiple 
reaction monitoring over 2.0–3.5 orders of magnitude. 
Mean intra-assay and inter-assay accuracies range from 
85% to 112%, and intra-assay and inter-assay imprecision 
do not exceed 15% for any analyte.
sample size
Because of limited knowledge about paracetamol metab-
olites in neonates and since the correlation between 
these metabolites and threshold for hepatotoxicity is 
unknown, sample size calculation is impossible, that is, 
this is an explorative and hypothesis generating study.
Previous studies,2–4 investigating intravenous parac-
etamol administrations up to 3 days, included 15, 35 
and 50 patients, respectively. It was therefore decided 
to include a minimum of 60 patients and a maximum 
of 120 patients. The study is stopped when 120 patients 
who receive paracetamol for >3 days are included or on 
30 April 2019.
data
Data will be managed by an electronic data capture tool 
(REDCap) hosted at the Capital Region of Denmark. 
Figure 2 Study design. ALT, alanine aminotransferase; BILI, bilirubin. 
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REDCap is a secure, web-based application designed to 
support data capturing for research.38 REDCap provides 
an intuitive interface for validated data entry; second, 
trails for tracking data manipulation and export proce-
dures, and automated export procedures for seamless 
data downloads to common statistical packages and ulti-
mately, procedures for importing data from external 
sources. For analyses the data will be exported to SAS 
and the software R V.3.5.1 to create a comma-separated 
input data file that is readable for software for non-linear 
mixed effect modelling, NONMEM.
Pharmacokinetic and pharmacodynamics modelling
Structural and stochastic model development
During the data compilation, the paracetamol plasma 
concentrations will be logarithmically transformed prior 
to modelling, and concentration-time data will be fitted 
to both one and two compartment models with first-
order elimination for the disposition. Different models to 
characterise the absorption will be tested for the oral-ad-
ministrated paracetamol. Interindividual variability and 
interoccasion variability will be tested in relationship 
to the pharmacokinetic parameters. Both exponential, 
proportional and combined residual error models will be 
tested.
Covariate model
Once the base model (structural and stochastic model 
combined) have been identified, the influence of the 
different covariates (eg, weight, length, body mass 
index) will be tested on the pharmacokinetic parame-
ters, possible correlation will be identified through visual 
inspection. If possible, relevant covariates will be tested 
on relevant parameters, as judged by visual inspection, in 
stepwise forward and backward deletion using the step-
wise covariate model tool (PsN).
Simulation
COMFORT neo pain scores and population pharmacoki-
netic analysis of paracetamol samples will be analysed 
simultaneously. An E max model with lag time will be 
tested for pain. The pharmacodynamics relationship 
with the paracetamol concentration and COMFORT 
neo scores will only be assessed in the periods where 
the patients receive paracetamol as the only analgesic. 
However, the longitudinally COMFORT neo scores might 
hold important data on the pain history over time.
Model evaluation
Selection criteria for final model will be evaluated using 
prediction-corrected visual predictive checks and boot-
strap analysis, a statistic significant level of p<0.05 improve-
ment of fit will be used.
EthICs And dIssEMInAtIon
As this study follows normal dosing strategies, the poten-
tial risks relate to the additional blood samples (0.2 mL 
for paracetamol and metabolites and 0.4 mL for ALT and 
bilirubin). Blood samples from heel pricks are consid-
ered low risk39 when performed by experienced staff. 
Blood samples will be drawn from indwelling catheters 
whenever possible to minimise pain or taken by heel 
prick by experienced NICU staff. Blood loss will not 
exceed 3% of total blood volume (which corresponds 
to 2.4–2.7 mL/kg) over a 4-week period or 1% of total 
blood volume at any single blood draw.40 The loss will be 
monitored closely. Clinical samples will be given priority 
over study-specific samples. The samples are stored until 
they can be shipped for analyses at the Center for Human 
Toxicology, University of Utah.
Informed consent will be signed by both parents or legal 
guardian(s). To reduce parental stress following the process 
of consent and to provide more time for information, inclu-
sion can be postponed 24 hours from the first dose of parac-
etamol has been administered. ALT and bilirubin should 
preferably be measured before first administration of parac-
etamol. However, it is accepted that they are obtained within 
24 hours from first administration (inclusion after treat-
ment start and delay of hepatic biomarkers was included in 
Amendment B approved August 2018).
Normal procedures apply for reporting adverse events 
and adverse reactions to the Danish Medicines Agency. 
In relation to the study, only unknown or serious adverse 
events, and reactions and unexpected serious adverse 
reactions will be reported to the Danish Medicines 
Agency and the Ethics Committee.
PErsPECtIvEs
At present, few hepatic safety data exist on prolonged 
paracetamol treatment. All results from the current 
study will be published in peer-reviewed scientific jour-
nals regardless of the findings. After publication, the 
main results will be available at  clin ical tria lsre gister. 
eu. Furthermore, the study may generate information 
used in future national and international guidelines for 
prolonged treatment of pain in neonates.
This study was approved by the Regional Ethics 
Committee case no.: H-17027244, the Danish Medicines 
Agency EudraCT: 2017-002724-25 and the Danish Data 
Protection Agency: BFH-2017–106, I-Suite no.: 05952.
The two sites were initiated by the Good Clinical Prac-
tice (GCP) units at Copenhagen University and Aarhus 
University in February 2018. The first patient was included 
in April and June 2018, respectively. The GCP units will 
monitor the study in accordance with the ICH Harmon-
ised Tripartite Guideline for GCP.
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